

Haematologica  
HAEMATOL/2017/176917  
Version 3

Predictive value of MRD in Ph+ ALL treated with imatinib in the EsPhALL study, based on IG/TR and BCR/ABL1 methodologies

Giovanni Cazzaniga, Paola De Lorenzo, Julia Alten, Silja Röttgers, Jeremy Hancock, Vaskar Saha, Anders Castor, Hans O Madsen, Virginie Gandemer, Hélène Cavé, Veronica Leoni, Rolf Köhler, Giulia M Ferrari, Kirsten Bleckmann, Rob Pieters, Vincent Van der Velden, Jan Stry, Jan Zuna, Gabriele Escheric, Udo zur Stadt, Maurizio Aricò, Valentino Conter, Martin Schrappe, Maria Grazia Valsecchi, and Andrea Biondi

Disclosures: All authors declare that they have no conflicts of interest. Novartis provided the drug for the EsPhALL clinical study, and this project was partially funded by the grants listed below. The sponsors had no role in study design, data collection, data analysis, data interpretation, or writing of the report. All authors had full access to all the data in the study and had final responsibility for decision to submit for publication.

Contributions: GC, PDL, MGV and AB designed and planned the study. VC, PDL, GC and MGV wrote the report. PDL oversaw data pooling, data checking, reporting, and analyses. MGV was the study statistician. VS, AC, VG, VL, GMF, KB, RP, JS, GE, MA, MS, AB coordinated the clinical study in their own countries. GC coordinated the laboratories; GC, JA, SR, JH, HOM, HC, VvdV, JZ, UzS were responsible for the laboratory data in their group. All authors have revised and approved the final version of the report.